Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS
Published in Nature Medicine, 2026
A longitudinal proteomic study identifying a 19-protein plasma panel that predicts phenoconversion to clinical ALS up to 5 years in advance, outperforming neurofilament light chain alone.
Recommended citation: Ran X., Wuu J., Qin Z.S., McDermott M.P., Cooper-Knock J., Li Y., Granit V., Grignon A.L., Lin E., Fernandez M.C., Colato D., Carberry N., Lill C.M., Piazza P., Malaspina A., & Benatar M. (2026). "Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS." Nature Medicine.
Download Paper
